CRISPR Therapeutics AG
CRISPR Therapeutics AG (CRSP) is listed on NASDAQ and classified in Biotechnology, part of the Healthcare sector. It is headquartered in Zug, Switzerland. The company is worth $4.83B. Revenue was $3.51M in fiscal 2025, down 90.6% from the year before. It reported a net loss of $581.6M. The share price is 27.2% below its 52-week high of $68.71. 4 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Two Sigma (Two Sigma Investments), at $108.46M. In that quarter, 1 of them opened or added to the position and 1 reduced it. Over the last 30 days, company insiders sold $3.47M of its stock on the open market and bought none. $839.85K of those sales were scheduled in advance under 10b5-1 plans.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Major managers that reported this stock in their latest 13F.
▼ -38.4% over 5Y.
today you would have $539.25▼ -46.1%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 10 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $52.44 | $39.36 | $62.60 | $40.65 | $75.78 | $153.11 | $60.90 | $28.57 | $23.48 | $20.26 | |
| P/E | — | — | — | — | — | 16.1x | — | 52.1x | — | — | — |
| P/S | 123.3x |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| DFTXDefinium Therapeutics, Inc. | $36.00 | — | 5.3x | 0.00% | -64.09% | $4.84B |
| HTFLHeartflow, Inc. | $55.43 | — | 17.2x | 0.00% | -154.23% | $4.82B |
| LFSTLifeStance Health Group, Inc. | $12.56 | 96.6x | 3.2x | 0.00% | 3.43% | $4.77B |
| ERASErasca, Inc. | $14.04 |
| 1434.0x |
| 90.5x |
| 13.5x |
| 2668.6x |
| 6.4x |
| 16062.5x |
| 12.8x |
| 478.1x |
| 26.9x |
| 156.2x |
| P/B | 3.1x | 2.6x | 1.7x | 2.7x | 1.7x | 2.4x | 6.9x | 3.9x | 3.8x | 5.9x | 3.5x |
| EPS | -$6.47 | -$4.34 | -$1.94 | -$8.36 | $4.70 | -$5.29 | $1.17 | -$3.44 | -$1.71 | -$1.89 |
| Profit margin | -715.18% | -16569.77% | -981.54% | -41.38% | -54271.70% | 41.28% | -48520.86% | 23.09% | -5281.08% | -166.74% | -448.82% |
| ROE | -19.96% | -30.26% | -18.96% | -8.16% | -34.67% | 15.74% | -20.96% | 7.12% | -42.07% | -36.39% | -9.95% |
Median of the years shown; P/E years above 200x are left out.
| — |
| 12.1x |
| 0.00% |
| -78.25% |
| $4.91B |
| RGCRegencell Bioscience Holdings Ltd | $9.59 | — | 355.2x | 0.00% | -128.53% | $4.76B |
| MMEDMiniMed Group, Inc. | $17.49 | — | 1.4x | 0.00% | -8.66% | $4.92B |